Skip to Content

Eloxx Pharmaceuticals Inc ELOX

Morningstar Rating
$0.70 +0.02 (3.32%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ELOX is trading at a 352% premium.
Price
$0.70
Fair Value
$6.13
Uncertainty
Extreme
1-Star Price
$77.27
5-Star Price
$7.75
Economic Moat
Gqry
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ELOX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.68
Day Range
$0.520.70
52-Week Range
$0.407.96
Bid/Ask
$0.68 / $0.84
Market Cap
$2.20 Mil
Volume/Avg
18,484 / 6,347

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in the science of ribosome modulation, leveraging both its ZM chemistry technology platform and its library of novel aminoglycosides to develop novel oral small molecule Ribosome Modulating Agents (RMAs) and Eukaryotic Ribosome Selective Glycosides (ERSGs), for the treatment of rare and ultra-rare genetic diseases where patients have point nonsense genetic mutations that result in premature stop codons and less than full-length proteins. The ELX-02, the company's investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
18

Valuation

Metric
ELOX
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
ELOX
Quick Ratio
0.20
Current Ratio
0.24
Interest Coverage
−12.63
Quick Ratio
ELOX

Profitability

Metric
ELOX
Return on Assets (Normalized)
−136.52%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
ELOX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
WrwgwvksDwpz$589.6 Bil
Vertex Pharmaceuticals Inc
VRTX
ZqhqdkrKtmsrw$126.9 Bil
Regeneron Pharmaceuticals Inc
REGN
DvmsfhrbNqylsz$117.2 Bil
Moderna Inc
MRNA
TzynkmgBgw$46.4 Bil
Alnylam Pharmaceuticals Inc
ALNY
XfdptffbDyqtsh$30.1 Bil
argenx SE ADR
ARGX
VdvzfjvtXxz$28.0 Bil
BioNTech SE ADR
BNTX
WddmkpqbYgsq$20.6 Bil
Biomarin Pharmaceutical Inc
BMRN
VwxcfpvGgzlyv$16.0 Bil
United Therapeutics Corp
UTHR
ScyvslxkvZnzwt$14.6 Bil
Incyte Corp
INCY
ZgdtpsvvZnbwrvy$13.0 Bil

Sponsor Center